Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Notes Payables (2016 - 2017)

Moleculin Biotech (MBRX) has 2 years of Notes Payables data on record, last reported at $108000.0 in Q1 2017.

  • For Q1 2017, Notes Payables fell 82.44% year-over-year to $108000.0; the TTM value through Mar 2017 reached $108000.0, down 82.44%, while the annual FY2016 figure was $296000.0, N/A changed from the prior year.
  • Notes Payables reached $108000.0 in Q1 2017 per MBRX's latest filing, down from $296000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $615000.0 in Q1 2016 and bottomed at $108000.0 in Q1 2017.